Catalog No.: PC-72644Not For Human Use, Lab Use Only.
CFT-2718 (CFT2718) is a benzotriazoloazepine-based BRD4 degrader, rapidly and selectively degrade BRD4 in vitro in a CRBN-dependent manner (DC90=10 nM, 293T cells).
CFT-2718 (CFT2718) is a benzotriazoloazepine-based BRD4 degrader, rapidly and selectively degrade BRD4 in vitro in a CRBN-dependent manner (DC90=10 nM, 293T cells).
CFT-2718 is more effective than dinaciclib in controlling cell growth and efficiently reduces BRD4 expression in vitro (H69 cell IC50: 0.02 versus 17.38 nM).
CFT-2718 is more effective than dinaciclib in control of PDX tumor models in vivo.
CFT-2718 selectively increased the expression of cleaved PARP, an indicator of apoptosis.
CFT-2718 caused rapid BRD4 degradation and reduced levels of total and pSer2 RPB1 protein.
